Learn, Connect & Grow - Your Q2 People Pathways Update
Welcome to the Q2 Edition of Our People Pathways Newsletter!
Welcome to the Q2 Edition of Our People Pathways Newsletter!
Cambridge Enterprise sits at the heart of one of the world’s leading research ecosystems. As part of the University of Cambridge, we turn academic innovation into real-world impact through licensing, partnerships, spinouts and investment.
We support academics, researchers, staff and students in translating their ideas into practice, helping innovators, experts and entrepreneurs use commercial pathways to develop their work for the benefit of society, the economy, themselves and the University.
TTP is an employee-owned technology and product development consultancy, with a 40-year track record of partnering with ambitious clients to solve complex challenges and bring innovative, commercially successful solutions to market.
We invent, design, and manufacture impactful products and technologies across a wide range of industries – including healthcare, life science, energy, and communications – and at the intersection of engineering, physical science, and biology.
The UK Health Security Agency (UKHSA) prevents, prepares for and responds to infectious diseases, and environmental hazards, to keep all our communities safe, save lives and protect livelihoods.
We provide scientific and operational leadership, working with local, national and international partners to protect the public’s health and build the nation’s health security capability.
BURLINGAME, Calif., May 20, 2026 /PRNewswire/ -- Collaborative Drug Discovery (CDD), the leading provider of data management solutions for the pharmaceutical and biotechnology industries, today announced an agreement with Eli Lilly and Company (Lilly) to integrate Lilly TuneLab, a collaborative AI/ML drug discovery platform, into CDD Vault.
This webinar will discuss the impact of the Enlarged Board Simulation decision G1/19 and the UK Supreme Court Judgment in Emotional Perception on practice at the EPO and the UK IPO, particularly looking at appeal decisions. Although generally endorsing prior case law, G1/19 has prompted a greater level of concentration on ensuring that the requirements of patentability, especially technical character, are met over the whole scope of the claims. Emotional Perception directs UK examiners and courts to follow EPO practice more closely.
07:30 Departure to Cambridge
LONDON, UK, and COPENHAGEN, Denmark – May 14, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Neumirna Therapeutics (“Neumirna”) and is pleased to announce the placement of Dr. Ferenc Tracik as Chief Medical Officer (CMO).
MB097 used in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab)
Cambridge, UK – 18 May 2026: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that all primary and secondary objectives were met in its advanced melanoma (MELODY-1) Phase 1b trial.
*Guest blog by LimestoneGrey. If you would like to submit a guest blog please email [email protected].
Protecting Your Business in a Higher-Scrutiny R&D Tax Landscape